Like GLP-1, amylin is thought to slow gastric emptying, reduce glucagon secretion, increase satiety and reduce appetite, and to be frank, I personally didnt do a deeper dive on Amylin because when Novo Nordisk presented CagriSema at the ADA conference they were sparse on the details beyond talking up synergy with GLP-1
Frei B: Vitamin C as an antiatherogen: mechanism of action
Instead of giving your system a jolt, they work as precise signaling molecules that communicate with your cells, guiding your body toward optimal function
Peptide Therapy in the Context of South Florida: What Doral Patients Experience Miami and Doral present a specific patient profile that does not always match national peptide guides
Health experts dont know exactly why GLP-1 receptor agonists sometimes cause diarrhea, but they believe a couple of processes may be involved
Path 2: Moderate BMI + Serious Health Condition BMI of 30 or higher PLUS one of these: Heart failure (ask your doctor if you have "preserved ejection fraction" type) High blood pressure that's hard to control (still above 140/90 despite 2+ medicines) Chronic kidney disease (stage 3a or higher your doctor can confirm) Path 3: Lower BMI + Heart/Stroke History BMI of 27 or higher PLUS one of these: Pre-diabetes Previous heart attack Previous stroke Peripheral artery disease with symptoms (leg pain when walking) Important timing: These requirements are based on when you FIRST started the GLP-1 medication not your current weight or health